Novartis recently received FDA approval for its $2.1 million gene therapy drug—Zolgensma. With its pricing it becomes one of the richest in history. And of course that attracts private equity.
Private equity house Ampersand Capital Partners has acquired CDMO Vibralogics and intends to expand its capabilities to service the growing demand for gene therapy services. The price for the German contract development and manufacturing organization (CDMO) is not disclosed. Ampersand’s acquisition will help widen Vibralogics’ global research on the back of increased demand for viral vector and gene therapy services. The precision and personalization boom is on and private equity is circling the wagons.